Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

71.04USD
10 Dec 2018
Change (% chg)

$1.09 (+1.56%)
Prev Close
$69.95
Open
$70.04
Day's High
$71.30
Day's Low
$68.79
Volume
4,240,893
Avg. Vol
6,166,542
52-wk High
$74.92
52-wk Low
$54.48

Latest Key Developments (Source: Significant Developments)

Abbott Recommends Rejection Of Mini-Tender Offer By Baker Mills
Wednesday, 14 Nov 2018 09:00am EST 

Nov 14 (Reuters) - Abbott Laboratories ::ABBOTT RECOMMENDS REJECTION OF BELOW-MARKET MINI-TENDER OFFER BY BAKER MILLS LLC.ABBOTT LABORATORIES - RECEIVED NOTICE OF UNSOLICITED MINI-TENDER OFFER BY BAKER MILLS TO PURCHASE UP TO 60,000 ABBOTT COMMON SHARES.ABBOTT LABORATORIES - BAKER MILLS' OFFER PRICE OF $57.00 PER SHARE IN CASH.ABBOTT LABORATORIES - OFFER IS CURRENTLY SCHEDULED TO EXPIRE AT 5 P.M. NEW YORK CITY TIME ON MONDAY, DEC. 12, 2018.  Full Article

Abbott Laboratories Recommends Rejection Of Mini-Tender Offer By Baker Mills LLC
Wednesday, 14 Nov 2018 09:00am EST 

Nov 14 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES RECOMMENDS REJECTION OF MINI-TENDER OFFER BY BAKER MILLS LLC.ABBOTT - RECEIVED NOTICE OF UNSOLICITED MINI-TENDER OFFER BY BAKER MILLS LLC TO BUY UP TO 60,000 ABBOTT SHARES, OR SOME 0.003 PERCENT OF OUTSTANDING SHARES.ABBOTT LABORATORIES - BAKER MILLS' OFFER PRICE WAS $57.00 PER SHARE IN CASH.  Full Article

Abbott Introduces The Next Generation Of Influenza A & B And Strep A Assays With Fastest-Ever Time To Molecular Results
Thursday, 25 Oct 2018 09:00am EDT 

Oct 25 (Reuters) - Abbott Laboratories ::ABBOTT INTRODUCES THE NEXT GENERATION OF INFLUENZA A & B AND STREP A ASSAYS WITH FASTEST-EVER TIME TO MOLECULAR RESULTS.  Full Article

Abbott Unit Intends To Offer Senior Unsecured Notes
Wednesday, 19 Sep 2018 06:47am EDT 

Sept 19 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - UNIT OF CO INTENDS TO OFFER SENIOR UNSECURED NOTES IN OFFERING.ABBOTT - TO USE PROCEEDS TO REFINANCE ALL/PORTIONS OF OUTSTANDING 2.00% NOTES DUE 2020, 4.125% NOTES DUE 2020, AMONG OTHERS - SEC FILING.  Full Article

Abbott Sets Quarterly Dividend Of $0.28Per Share
Thursday, 13 Sep 2018 11:15am EDT 

Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.28PER SHARE.  Full Article

Clearstar Says Clearmd Mobile Drug Testing Solution Integrated With Abbott
Wednesday, 20 Jun 2018 02:00am EDT 

June 20 (Reuters) - CLEARSTAR INC ::CLEARMD MOBILE DRUG TESTING SOLUTION IS NOW INTEGRATED WITH ABBOTT LABORATORIES.  Full Article

Abbott Says Newest Generation Of Leading Heart Stent Now Approved In U.S. For People With Coronary Artery Disease
Wednesday, 23 May 2018 09:00am EDT 

May 23 (Reuters) - Abbott Laboratories ::ABBOTT - NEWEST GENERATION OF LEADING HEART STENT NOW APPROVED IN U.S. FOR PEOPLE WITH CORONARY ARTERY DISEASE.  Full Article

Abbott's Investigational Tendyne Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study
Wednesday, 23 May 2018 06:00am EDT 

May 23 (Reuters) - Abbott Laboratories ::ABBOTT'S INVESTIGATIONAL TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT DEMONSTRATES POSITIVE OUTCOMES AT 30 DAYS IN GLOBAL STUDY.DEVICE WILL BE FURTHER STUDIED IN U.S. PIVOTAL STUDY.  Full Article

5-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions
Tuesday, 22 May 2018 06:20am EDT 

May 22 (Reuters) - Abbott Laboratories ::FIVE-YEAR STUDY DATA CONFIRM POSITIVE OUTCOMES FOR PATIENTS WHEN ABBOTT DIAGNOSTIC TOOL WAS USED TO GUIDE HEART STENTING DECISIONS.  Full Article

Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation
Monday, 19 Mar 2018 09:00am EDT 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT'S MITRACLIP THERAPY RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PATIENTS WITH MITRAL REGURGITATION.ABBOTT LABORATORIES - ‍MITRACLIP SYSTEM IS APPROVED IN JAPAN FOR TREATMENT OF BOTH SEVERE DEGENERATIVE MITRAL REGURGITATION AND FMR HEART DISEASES​.ABBOTT-MINISTRY OF HEALTH LABOUR AND WELFARE IN JAPAN GRANTED NATIONAL REIMBURSEMENT FOR CO'S MITRACLIP THERAPY TO TREAT MITRAL REGURGITATION.  Full Article

Abbott resolves N.Y. claims over misleading infant-feeding surveys

Abbott Laboratories, the maker of Similac infant formula, has agreed to not falsely represent that surveys it mails new parents are for scientific research instead of marketing purposes and to accurately disclose their purpose.